Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: Results from the EXPO study
Alimentary Pharmacology and Therapeutics, Volume 22, No. 9, Year 2005
Notification
URL copied to clipboard!
Description
Background: Following initial healing of erosive oesophagitis, most patients require maintenance therapy to prevent relapse. Aim: To compare endoscopic and symptomatic remission rates over 6 months' maintenance therapy with esomeprazole or pantoprazole (both 20 mg once daily) in patients with healed erosive oesophagitis. Methods: Patients with symptoms of gastro-oesophageal reflux disease and endoscopically confirmed erosive oesophagitis at baseline were randomized to receive esomeprazole 40 mg or pantoprazole 40 mg for up to 8 weeks. Patients with healed erosive oesophagitis and free of moderate/severe heartburn and acid regurgitation at 4 weeks or, if necessary, 8 weeks entered the 6-month maintenance therapy phase of the study. Results: A total of 2766 patients (63% men; mean age 50 years) received esomeprazole 20 mg (n = 1377) or pantoprazole 20 mg (n = 1389) and comprised the intention-to-treat population. Following 6 months of treatment, the proportion of patients in endoscopic and symptomatic remission was significantly greater for those receiving esomeprazole 20 mg (87.0%) than pantoprazole 20 mg (74.9%, log-rank test P < 0.0001). Esomeprazole 20 mg produced a higher proportion of patients free of moderate to severe gastro-oesophageal reflux disease symptoms and fewer discontinuations because of symptoms than pantoprazole 20 mg (92.2% vs. 88.5%, P < 0.001). Conclusions: Esomeprazole 20 mg is more effective than pantoprazole 20 mg for maintenance therapy following initial healing of erosive oesophagitis and relief of gastro-oesophageal reflux disease symptoms. © 2005 Blackwell Publishing Ltd.
Authors & Co-Authors
Labenz, Joachim
Germany, Siegen
Ev. Jung-stilling-krankenhaus Ggmbh
Armstrong, D.
Canada, Hamilton
Mcmaster University Medical Centre
Lauritsen, K.
Denmark, Odense
Odense Universitetshospital
Katelaris, P.
Australia, Sydney
The University of Sydney
Schmidt, S.
South Africa, Cape Town
Burnside House
Schütze, K.
Austria, Vienna
Hanusch-krankenhaus
Wallner, G.
Poland, Lublin
Medical University of Lublin
Juergens, H.
Germany
Gastroenterology Specialist Centre
Preiksaitis, H.
Canada, London
Western University
Keeling, N.
Sweden, Sodertalje
Astrazeneca Sweden
Nauclér, Emma C.
Sweden, Sodertalje
Astrazeneca Sweden
Adler, J.
Sweden, Sodertalje
Astrazeneca Sweden
Eklund, S.
Sweden, Sodertalje
Astrazeneca Sweden
Statistics
Citations: 83
Authors: 13
Affiliations: 10
Identifiers
Doi:
10.1111/j.1365-2036.2005.02643.x
ISSN:
02692813
Study Design
Cross Sectional Study
Participants Gender
Male